Amgen
Presence
Amgen is one of the...
- Forbes Global 2000 (#193);
- Fortune 500 (#151);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Amgen is a company listed under the stock ticker AMGN (US).
Amgen has a direct presence in 21 countries.Amgen has 24 subsidiaries including Amgen APAC, Amgen Argentina and Amgen Australia.
They are in:
- Pharmaceuticals84%
- Biotechnology16%
Acquisition, funding and merger involving Amgen.
- Amgen Rare Disease and Amgen have announced they will merge (posted on October 10 2023)..
- Amgen has announced the acquisition of Amgen Rare Disease (posted on December 12 2022).
- Amgen has acquired ChemoCentryx (posted on October 21 2022).
Executives
View the org chart displaying its 218 main executives
Most searched biographies at Amgen
Create your alert
to follow the executive moves at Amgen.
Pharmaceuticals
Amgen has 1,837 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).
Popular M&A news in Pharmaceuticals
- Molex has announced the acquisition of Vectura Group (posted on September 23 2024).
- Agilent Technologies has acquired BioVectra (posted on September 23 2024).
- OXB will change its company name to OXB on Sep 18, 2024. (posted on September 18 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Amgen
- TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
- AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
- AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
- AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
- AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
- OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS
- AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS
- FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
- AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
- View more press releases Close
Social media about Amgen
- Amgen on Wikipedia, Google News & Yahoo Finance
- Amgen on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Robert Bradway 
